Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 basket study of VIR-5818 as a monotherapy, and in combination with pembrolizumab in multiple tumor types, including metastatic breast cancer and metastatic colorectal cancer

Next Previous
X
Search
Trial Profile

A Phase 1 basket study of VIR-5818 as a monotherapy, and in combination with pembrolizumab in multiple tumor types, including metastatic breast cancer and metastatic colorectal cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; SAR 446309 (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Vir Biotechnology

    • Most Recent Events

    • 06 Nov 2024 New trial record
    • 31 Oct 2024 According to a Vir Biotechnology media release, company plans to share initial clinical data for VIR-5818 in the first quarter of 2025. This phase 1 study is on-going in multiple tumor types.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top